PeptideStack
5.2kquestions
20kanswers
220users

How do I check that two FGP lots of cagrilintide agree on content assay?

Asked 15 Mar 2025Modified 12 months agoViewed 39k times
37

For reference: FGP · cagrilintide.

This is not behaving the way I expected and I want to understand the discrepancy before I act on it.

I have photographed the current state and recorded the conditions, so I can answer follow-up questions precisely.

Is this recoverable, and how would I tell?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
shareeditfollowflag
VF
askedvial_five12k1715 Mar 2025
4Is the comparison against a supplier certificate or against a second independent result? – otto_brenner 6 months ago
3Voting to keep this open — it is more specific than it first looks. – e_dziedzic 4 months ago
add a comment

5 Answers

Sorted by votes
81

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

Specifically, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 29 Jul 2025 by Dr_Ingrid_Baumgartner — updated for the 2026 guidance change

shareimprove this answerflag
DB
answeredDr_Ingrid_Baumgartner73k587 Jul 2025
6The distinction between purity and content cannot be repeated often enough here. – p_mkhize 9 months ago
5Same experience here, different supplier. – anders_vestby 7 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
53

Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
AN
answeredamara_nwachukwu20k2720 Mar 2025
2Thank you — this is the answer I was looking for. – bufferline42 8 months ago
add a comment
42

A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Specifically, a statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
NT
answeredn_takahashi29k3831 Mar 2025
34

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
TM
answeredthabo_maseko28k3811 Apr 2025
26

More usefully, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
DB
answeredDr_Ingrid_Baumgartner73k5822 Apr 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.